These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 9678133)

  • 1. Oral contraceptives and venous thromboembolism: an epidemiological review.
    Lidegaard O
    Eur J Contracept Reprod Health Care; 1996; 1(1):13-20. PubMed ID: 9678133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study.
    Lidegaard O
    Acta Obstet Gynecol Scand; 1997 Mar; 76(3):252-60. PubMed ID: 9093141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral contraceptive use and venous thromboembolism: a consideration of the impact of bias and confounding factors on epidemiological studies.
    Rekers H; Norpoth T; Michaels MA
    Eur J Contracept Reprod Health Care; 1996; 1(1):21-30. PubMed ID: 9678134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN; Slawson JG
    J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
    [No Abstract]   [Full Text] [Related]  

  • 6. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modern oral contraceptives and cardiovascular disease.
    Rosenberg L; Palmer JR; Sands MI; Grimes D; Bergman U; Daling J; Mills A
    Am J Obstet Gynecol; 1997 Sep; 177(3):707-15. PubMed ID: 9322646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk from third-generation progestogens: fuzzy logic or fuzzy science?
    Corson SL
    J Reprod Med; 1996 Sep; 41(9):711-2. PubMed ID: 8887199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new pills: awaiting the next generation of oral contraceptives.
    Klitsch M
    Fam Plann Perspect; 1992; 24(5):226-8. PubMed ID: 1426186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer oral contraceptives and the risk of venous thromboembolism.
    Walker AM
    Contraception; 1998 Mar; 57(3):169-81. PubMed ID: 9617533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
    Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare".
    Heinemann LA; Dinger JC; Assmann A; Minh TD
    Contraception; 2010 May; 81(5):401-7. PubMed ID: 20399946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
    Winkler UH
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of a large-scale surveillance system in Planned Parenthood Federation of America clinics to monitor cardiovascular events in users of combination oral contraceptives.
    Burnhill MS
    Int J Fertil Womens Med; 1999; 44(1):19-30. PubMed ID: 10206196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptives and venous thromboembolism.
    Paul C
    N Z Med J; 1996 Nov; 109(1033):413-5. PubMed ID: 8941290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral contraceptives and venous thromboembolism: consensus conference statement.
    Dialogues in Contraception Consensus Conference (1995: Chicago)
    Dialogues Contracept; 1996; ():1-8. PubMed ID: 12320455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
    Schwingl PJ; Shelton J
    Contraception; 1997 Mar; 55(3):125-9. PubMed ID: 9114999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
    BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.